Intradermal delivery of receptor‐binding domain of SARS‐CoV‐2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. Issue 1 (12th December 2020)

• Record Type: Journal Article
• Authors: Kuwentrai, Chaiyaporn; Yu, Jinming; Rong, Li; Zhang, Bao‐Zhong; Hu, Ye‐Fan; Gong, Hua‐Rui; Dou, Ying; Deng, Jian; Huang, Jian‐Dong; Xu, Chenjie
• Is Part Of: Bioengineering & translational medicine. Volume 6:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-12
• Subjects: COVID‐19 -- intradermal delivery -- microneedle -- receptor‐binding domain -- SARS‐CoV‐2 -- spike protein; Bioengineering -- Periodicals; Drug development -- Periodicals; Drugs -- Testing -- Periodicals; 660.6
• DOI: 10.1002/btm2.10202
• Languages: English
• ISSNs: 2380-6761

Abstract

Abstract: The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein contains an immunogenic receptor‐binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S‐RBD vaccine using a dissolvable microneedle skin patch can induce both significant B‐cell and significant T‐cell responses against S‐RBD. Importantly, the outcomes were comparable to that of conventional bolus injection.